Metronomic Chemotherapy is an Effective and Well Tolerated Treatment in Advanced Triple Negative Breast Cancer Patients: A Case Report of a Very Long Responder and Literature Review

Abstract

Triple negative breast cancer (TNBC) represents a heterogeneous entity characterized by aggressive clinical course, early recurrence and relatively poor survival in advanced stages. Currently available chemotherapy regimens are generally associated with unfavourable adverse events (Aes) that can lead to treatment discontinuation, mostly in frail patients (such as older patients). In this complex scenario, metronomic chemotherapy is acquiring an increasingly important role thanks to its effectiveness and its manageable safety profile. Although median survival remains poor for metastatic TNBC (mTNBC), we report the case of a patient who experienced a very long response to metronomic chemotherapy, both in first-and second line treatment.